A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Coverage achievable with two-week gap before premature birth
- Vaccination in the third trimester still provides significant infant protection
Strong evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study conducted across England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing strong and reliable information of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation provides healthcare professionals and parents-to-be with assurance in the vaccine’s proven efficacy across varied populations and settings.
The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology measured practical outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to breathe and feed adequately. Parents commonly see their babies fighting for breath, their chests heaving as they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants recover with supportive care, a limited though important proportion perish from RSV complications annually, making vaccination as prevention a essential public health priority for protecting the most vulnerable and youngest people in our communities.
- RSV produces inflammation in lungs, resulting in serious respiratory problems in babies
- Approximately half of newborns contract the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- Few infants succumb to RSV related complications each year in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These regional differences reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts launching diverse outreach initiatives to connect with women during pregnancy
- Inconsistencies across regions in vaccine uptake rates across England require targeted improvement
- Community health services adapting programmes to align with community needs and circumstances
Practical implications and parental perspectives
The vaccine’s impressive effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the rollout of this preventative solution, the 80% decrease in admissions represents thousands of infants spared from severe infection. Parents no more face the troubling prospect of seeing their babies struggle for breath or difficulty feeding, symptoms that define severe RSV infections. The vaccine has markedly changed the landscape of neonatal breathing health, giving expectant mothers a proactive tool to safeguard their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab emphasises the life-altering consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women during their late pregnancy, changing what was once an inevitable seasonal threat into a controllable health concern.